G4S Plc/ US37441W1080 /
- - | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
-USD | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | - | - |
GlobeNewswire
4/16
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization o...
GlobeNewswire
4/10
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer R...
GlobeNewswire
4/9
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a N...
GlobeNewswire
2/5
Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in...
GlobeNewswire
1/25
Atlas Air Worldwide Announces Appointment of Joel Goldberg as Executive Vice President and Chief Inf...
GlobeNewswire
11/14/2023
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
GlobeNewswire
11/7/2023
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Tre...
GlobeNewswire
10/23/2023
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conf...
GlobeNewswire
9/27/2023
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Canc...
GlobeNewswire
8/17/2023
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment...
GlobeNewswire
8/15/2023
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 3...
GlobeNewswire
3/22/2022
Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research...
GlobeNewswire
3/15/2022
Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation o...
GlobeNewswire
2/23/2022
Brink’s Reports Record Revenue and Operating Profit for Fourth-Quarter and Full-Year
GlobeNewswire
2/15/2022
Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR ...
GlobeNewswire
2/1/2022
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of L...
GlobeNewswire
1/18/2022
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from Univers...